ClinicalTrials.gg
RecruitingNCT07383103Updated Mar 4, 2026

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

A Phase 4 interventional study of Hydrocortisone plus Fludrocortisone and Standard care in Septic Shock, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Northern Jiangsu People's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing hydrocortisone in Shock, Septic — 2 open to participants now, 3 under way, 1 of them phase 3. Hydrocortisone · Shock, Septic.

Planned enrollment
7th of 20
336 · median 121
Started
2026
the only one that year
Phase 4
7 of 20
2 open now
Registered
20th of 20
by date
Lead sponsor
3 of 20
Northern Jiangsu People's Hospital

Among the 20 studies testing hydrocortisone in Shock, Septic, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 7 in phase 4, and was the 20th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 20 studies testing hydrocortisone in Shock, Septic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About hydrocortisone

Hydrocortisone: first FDA approval 1951 (HYDROCORTONE), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing hydrocortisone in Shock, Septic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.

Read the detailed description

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and septic shock represents its most severe form, characterized by profound circulatory and metabolic abnormalities with high mortality.

Current international guidelines recommend intravenous hydrocortisone as adjunctive therapy in patients with septic shock who remain hypotensive despite adequate fluid resuscitation and vasopressor treatment. However, critically ill patients may exhibit relative deficiencies of both glucocorticoid and mineralocorticoid activity, and hydrocortisone alone may not fully meet the physiological demands under severe stress. In recent years, combination therapy with hydrocortisone and fludrocortisone has been investigated, but published trials have reported inconsistent results regarding mortality, shock reversal, and adverse events.

Therefore, this randomized controlled trial aims to evaluate the efficacy and safety of hydrocortisone combined with fludrocortisone, compared with standard therapy, in patients with septic shock.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • septic shock
  • hydrocortisone
  • fludrocortisone
  • mortality
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following conditions will be excluded:

  1. Systemic therapy within the last 3 months before septic shock;
  2. High-dose steroid therapy;
  3. ;
  4. Pregnant;
  5. Known allergy to hydrocortisone or fludrocortisone;
  6. Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting;
  7. Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);
  8. Refusal of the attending staff or patient family;
  9. Current participation in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    Hydrocortisone plus Fludrocortisone

    Hydrocortisone: 200 mg per day administered by continuous intravenous infusion for up to 7 days or until ICU discharge, whichever occurs first. Fludrocortisone: 50 μg administered orally or via nasogastric tube once daily for up to 7 days or until ICU discharge, whichever occurs first.

    Drug: Hydrocortisone plus Fludrocortisone

  • Active comparator
    Standard care

    Patients will receive standard care for septic shock according to current international guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures, including the use of hydrocortisone at the discretion of the treating physician, but without fludrocortisone.

    Other: Standard care

Interventions

  • DrugHydrocortisone plus Fludrocortisone

    Drug pages: HydrocortisoneStudies of HydrocortisoneHydrocortisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FludrocortisoneStudies of FludrocortisoneFludrocortisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hydrocortisone will be administered at a dose of 200 mg per day by continuous intravenous infusion. Fludrocortisone will be administered at a dose of 50 μg once daily orally or via nasogastric tube. Both drugs will be given for up to 7 days or until ICU discharge, whichever occurs first.

    Also known as: Hydrocortisone Injection, Fludrocortisone Acetate Tablets

  • OtherStandard care

    Patients will receive standard care for septic shock according to current international and institutional guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures. Fludrocortisone will not be administered.Hydrocortisone may be administered at the discretion of the treating physician.

06

What researchers measure

Primary outcomes

  1. 90-day mortality

    All-cause mortality at day 90 after randomization

    Time frame: 90 days after randomization

Secondary outcomes

  1. 28-day mortality

    All-cause mortality at day 28 after randomization

    Time frame: 28 days after randomization

  2. ICU mortality

    All-cause mortality at ICU discharge

    Time frame: From randomization to ICU discharge (up to 90 days)

  3. Hospital mortality

    All-cause mortality at hospital discharge

    Time frame: From randomization to hospital discharge (up to 90 days)

Other outcomes

  1. Shock reversal time

    Reversal of shock is defined as the maintenance of a systolic blood pressure of at least 90 mmHg without vasopressor support for at least 24 h. Time to shock reversal is defined as the time from randomization to shock reversal.

    Time frame: From randomization up to 28 days

  2. ICU length of stay

    Time in days until ICU discharge

    Time frame: From randomization to ICU discharge (up to 90 days)

  3. Hospital length of stay

    Time in days until hospital discharge

    Time frame: From randomization to hospital discharge (up to 90 days)

  4. Change in Sequential Organ Failure Assessment (SOFA) score at 72 hours

    The Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction and worse clinical outcomes. The change in SOFA score (ΔSOFA) is calculated as the SOFA score at enrollment minus the SOFA score at 72 hours after randomization. If a patient is discharged from the ICU within 72 hours, the SOFA score at ICU discharge will be used for analysis.

    Time frame: 72 hours after randomization

  5. 72h lactate

    lactate level at 72h after randomization

    Time frame: 72 hours after randomization

  6. 72h P/F

    P/F at 72h after randomization

    Time frame: 72 hours after randomization

  7. ICU-free days up to day 28

    Total number of days alive and free of ICU stay during the 28 days after randomization.

    Time frame: 28 days after randomization

  8. Vasopressor-free days up to day 28

    Total number of days alive and free of vasopressor during the 28 days after randomization.

    Time frame: 28 days after randomization

  9. Ventilator support-free days up to day 28

    Total number of days alive and free of ventilator support during the 28 days after randomization.

    Time frame: 28 days after randomization

  10. CRRT-free days up to day 28

    Total number of days alive and free of CRRT during the 28 days after randomization.

    Time frame: 28 days after randomization

07

Study locations

1 of 1 sites recruiting
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
    Recruiting
    • Qingquan Lyu, Master · Contactbonhomie2014@163.com · 0086-18051063899
    • Xiaohua Gu, Master · Contactnjguxiaohua@163.com · 0086-18051062325
    • Qingquan Lyu, Master · Principal investigator
    • Xiaohua Gu, Master · Sub investigator
    • Ruiqiang Zheng, Bachelor · Sub investigator
    • Jiangquan Yu, Doctor · Sub investigator
    • Ying Shi, Master · Sub investigator
    • Yuanjin Pan, Bachelor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 33 months is above that.

Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2026
First posted
Feb 3, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383103
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
Qing-quan Lv (Principal Investigator, Northern Jiangsu People's Hospital) — Principal investigator
First posted
Feb 3, 2026
Start date
Mar 2, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Qingquan Lyu, Master
Contact
bonhomie2014@163.com
0086-18051063899
Xiaohua Gu, Master
Contact
njguxiaohua@163.com
0086-18051062325
Qingquan Lyu, Master
principal investigator · Northern Jiangsu People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydrocortisone · Fludrocortisone

Start the discussion